Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma

Cancer

Volumn 101, Issue 1, 2004, Pages 90-95

  Rini, Brian I ^a   Weinberg, Vivian ^a   Shaw, Vanessa ^a   Scott, Janet ^a   Bok, Robert ^a   Park, John W ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EpCAM; Renal cell carcinoma; Time to disease progression; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; ATROPINE; CELL ADHESION MOLECULE; CIMETIDINE; DEXAMETHASONE; EPITHELIAL CELL ADHESION MOLECULE; GRANISETRON; ORAL ANTIDIABETIC AGENT; PROTEIN KINASE C; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; EPILEPTIC AURA; FATIGUE; FEMALE; GENE INACTIVATION; HEADACHE; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; LACRIMATION; MALE; METASTASIS; MOOD DISORDER; MYALGIA; NAUSEA; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; PRURITUS; SCOTOMA; SWEATING; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL ADHESION MOLECULES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; STAUROSPORINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042582607     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20313     Document Type: Article

References (25)

1. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972-2980.
2. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17:2521-2529.
3. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22:42-60.
4. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
5. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90.
6. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 1994;91:9700-9704.
7. Nishizuka Y. The protein kinase C family and lipid mediators for transmembrane signaling and cell regulation. Alcohol Clin Exp Res. 2001;25(5 Suppl. ISBRA):3S-7S.
8. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem. 1997;272:27509-27512.
9. Pal S, Claffey KP, Cohen HT, Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem. 1998;273:26277-26280.
10. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot (Tokyo). 1987;40:1782-1784.
11. Takahashi I, Saitoh Y, Yoshida M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot (Tokyo). 1989;42:571-576.
12. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia. 2001;15:1-9.
13. Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol. 2000;27:560-577.
14. Tamura T, Sasaki Y, Minami H, et al. Phase I study of UCN-01 by 3-hour infusion [abstract]. Proc Am Soc Clin Oncol. 1999;18:A611.
15. Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
16. Park JW, Scott J, Seo TH, et al. Comparative evaluation of micrometastasis (MM) in primary breast cancer as detected by immunocytochemistry (ICC), flow cytometry (FC), and reverse transcription-polymerase chain reaction (RT-PCR) [abstract]. Proc Am Soc Clin Oncol. 2002;21:430a.
17. Racila E, Euhus D, Weiss AJ, et al. Detection and charaterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95:4589-4594.
18. Motzer R, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
19. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20:303-321.
20. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427.
21. Braun S, Hepp F, Kentenich CR, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res. 1999;5:3999-4004.
22. Ghossein RA, Bhattacharya S. Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin Surg Oncol. 2001;20:304-311.
23. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741-746.
24. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478-4484.
25. Schwartz LN, Mazumdar M, Wang L, et al. Response assessment classification in patients with advanced neural cell carcinoma treated on clinical trials. Cancer. 2003;98:1611-1619.